Please assess the completion status of the following clinical trial:

Trial Title: GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.~* Women of childbearing potential must use an acceptable method of contraception~Phase 1~Subjects with the the following:~* Regimen A and B:~  * pancreatic adenocarcinoma,~ * esophageal adenocarcinoma, or esophageal squamous cell carcinoma, or~ * gastric/gastroesophageal junction adenocarcinoma, or~ * TNBC, or~ * prostate cancer, or~ * colorectal adenocarcinoma, or subjects with tumor types that have progressed after receiving initial treatment benefit rom the last single agent checkpoint inhibitor that is approved for the indication or in combination with standard of care therapy, for example, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, renal cell carcinoma, and hepatocellular carcinoma, etc.~* Regimen C: newly diagnosed stage IV pancreatic cancer~Phase 2~* Cohort 1: pancreatic cancer.~* Cohort 2: colorectal cancer~* Cohort 3: gastric/GEJ adenocarcinoma~Exclusion Criteria:~* History of another malignancy within 2 years prior to first study drug(s) administration, unless the malignancy was treated with curative intent and the likelihood of relapse is \<5% in 2 years~* Pregnant or nursing~* Known history of testing positive for human immunodeficiency virus (HIV)~* Gastrointestinal (GI) tract disease causing the inability to take oral medication.~* Positive test for Hepatitis B virus surface antigen (HBsAg) or a and/or positive Hep C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.~Other protocol-defined inclusion/exclusion criteria will apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Regimen A - GB1275 monotherapy (Type: EXPERIMENTAL): GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
- Phase 1: Regimen B - GB1275 with an Anti-PD-1 (Type: EXPERIMENTAL): GB1275 with pembrolizumab dose escalation and expansion:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).
- Phase 1: Regimen C - GB1275 with Standard of Care (SOC) (Type: EXPERIMENTAL): GB1275 with SOC dose escalation:~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)
- Phase 2: Cohort 1 - GB1275 with SOC (Type: EXPERIMENTAL): GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI.
- Phase 2: Cohort 2 - GB1275 with an Anti-PD-1 (Type: EXPERIMENTAL): GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).
- Phase 2: Cohort 3 - GB1275 with an Anti-PD-1 (Type: EXPERIMENTAL): GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).

Based on this trial design, predict the completion outcome and termination type (if applicable).